Their vaccine Pfizer-BioNTech against Covid-19 is 73% more effective in protecting babies – aged 6 months to 4 years – during which the Omicron variant of the coronavirus was extremely commonPharmaceutical company Pfizer announced this on Tuesday.
On June 17, the US Food and Drug Administration (FDA) gave approval for the vaccine to this age group.
Infants in the study received either three doses (3 mcg) of the Pfizer-BioNTech vaccine or a placebo. According to results published by two pharmaceutical companies, the vaccine was 73.2% effective in children aged 6 months to 4 years.
“While these results confirm that three 3µg doses of our Covid-19 vaccine provided infants with a high level of protection at a time when the Omicron BA.2 sub-variant was widely available, (…) we are also developing a bivalent Omicron BA vaccine. The .4/BA.5 vaccine is specifically designed for this age group to fight these sub-options,” said Ugur Sahin, CEO and co-founder of BioNTech.
Source: RES-IPE
Source: Kathimerini
Anna White is a journalist at 247 News Reel, where she writes on world news and current events. She is known for her insightful analysis and compelling storytelling. Anna’s articles have been widely read and shared, earning her a reputation as a talented and respected journalist. She delivers in-depth and accurate understanding of the world’s most pressing issues.